SlatopolskyE., CaglarS., PennellJ.P., ToggartJ., CanterburyJ., ReissE., BrickerN.S.On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog.J Clin Invest1971; 50: 497–9.
2.
MartinezI., SarachoR., MontenegroJ., LlachF.The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure.Am J Kidney Dis1997; 29: 496–502.
3.
De BoerI.H., GorodetskayaI., YoungB.. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-Dependent, racedependent, and associated with cardiovascular disease.J Am Soc Nephrol2002; 13: 2762–9.
4.
LevinA., BakrisG.L., MolitchM.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.Kidney Int2007; 71: 31–8.
5.
Al-BadrW., MartinK.J.Vitamin D and kidney disease.Clin J Am Soc Nephrol2008; 3: 1555–60.
6.
BrownA.J., SlatopolskyE.Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.Nat Clin Pract Endocrnol Metab2007; 3: 134–44.
HilpertJ., WogensenL., ThykjaerT.. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism.Kidney Int2002; 62: 1672–81.
9.
RavaniP., MalbertiF., TripepiG.. Vitamin D levels and patients outcome in chronic kidney disease.Kidney Int2009; 75: 88–95.
10.
SlatopolskyE., Role of phosphorous in the pathogenesis of secondary hyperparathyroidism.Am J Kidney Dis2001; 37 (Suppl): S54–57.
11.
LiuS., TangW., ZhouJ.. Fibroblastic growth factor 23 is a counter-regolatory phosphaturic hormone for vitamin D.J Am Soc Nephrol2006; 17: 1305–15.
LarssonT.Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.Kidney Int2003; 64: 2272–79.
14.
GutierrezO., IsakovaT., RheeE.. Fibroblastic growth factor 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.J Am Soc Nephrol2005; 16: 2205–15.
15.
UrakawaI.Klotho converts canonical FGF receptor into a specific receptor for FGF23.Nature2006; 444: 770–4.
16.
KohN.Severely reduced production of klotho in human chronic renal failure kidney.Biochem Biophys Res Commun2001; 280: 1015–20.
17.
IsakovaT., GutierrezO., ShahA., CastaldoL., HolmesJ., LeeH., WolfM.Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.J Am Soc Nephrol2008; 19: 615–23.
18.
BrownE.M.Clinical lesons from the calcium-sensing receptor.Nat Clin Pract Endocrinol Metab2007; 3: 122–33.
19.
HoC.A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.Nat Genet1995; 11: 389–94.
20.
LiY.C.Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin d receptor-ablated mice.Endocrinology1998; 139: 4391–6.
21.
KosC.H.The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone.J Clin Invest2003; 111: 1021–8.
22.
GoodmanW.G.Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease.Curr Opin Nephrol Hypertens2005; 14: 355–60.
23.
BrownA.J.Rat calcium-sensing receptor is regulated by vitamin D but not by calcium.Am J Physiol1996; 270: F454–60.
24.
MaitiA., BeckmanM.J.Extracellular calcium is a direct effector of VDR levels in proximal tubule epitelial cells that counter-balances effects of PTH on renal vitamin D metabolism.J Steroid Biochem Mol Biol2007; 103: 504–8.
25.
KiforO., MooreF.D., WangP., WhiteM.Reduced immuno-staining for extracellular Ca2+-sensing receptor in primary or secondary uremic hyperpara- thyroidism.J Clin Endocrinol Metab1996; 81: 1598–606.
26.
FukudaN., TanakaH., TominagaY., FukagawaM., KurokawaK.Decreased 1,25 dihydroxyvitamin D receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.J Clin Invest1993; 92: 1436–43.
27.
MalbertiF., CorradiB., CosciP., CalliadaF., MarcelliD., ImbasciatiE.Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.Am J Kidney Dis1996; 28: 704–12.
28.
BerndtT., ThomasL.F., CraigTa. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption.Proc Nat Acad Sci USA2007; 104: 11085–90.
29.
UsatiiM., RousseauL., DemersC.. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis.Kidney Int2007; 72: 1330–5.
